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Abstract
Background Atrial fibrillation (AF) is common in older people and is associated with increased stroke risk that may be reduced
by oral anticoagulation (OAC). Frailty also increases with increasing age, yet the extent of OAC prescription in older people
according to extent of frailty in people with AF is insufficiently described.
Methods An electronic health records study of 536,955 patients aged ≥65 years from ResearchOne in England (384 General
Practices), over 15.4 months, last follow-up 11th April 2017. OAC prescription for AF with CHA2DS2-Vasc ≥2, adjusted
(demographic and treatments) risk of all-cause mortality, and subsequent cerebrovascular disease, bleeding and falls were
estimated by electronic frailty index (eFI) category of fit, mild, moderate and severe frailty.
Results AF prevalence and mean CHA2DS2-Vasc for those with AF increased with increasing eFI category (fit 2.9%, 2.2;
mild 11.2%, 3.2; moderate 22.2%, 4.0; and severe 31.5%, 5.0). For AF with CHA2DS2-Vasc ≥2, OAC prescription was
higher for mild (53.2%), moderate (55.6%) and severe (53.4%) eFI categories than fit (41.7%). In those with AF and eligible
for OAC, frailty was associated with increased risk of death (HR for severe frailty compared with fit 4.09, 95% confidence
interval 3.43–4.89), gastrointestinal bleeding (2.17, 1.45–3.25), falls (8.03, 4.60–14.03) and, among women, stroke (3.63,
1.10–12.02).
Conclusion Among older people in England, AF and stroke risk increased with increasing degree of frailty; however, OAC
prescription approximated 50%. Given competing demands of mortality, morbidity and stroke prevention, greater attention
to stratified stroke prevention is needed for this group of the population.
Keywords: anticoagulation, atrial fibrillation, frailty, older people, stroke
Key points
• The prevalence of atrial fibrillation (AF) in people aged 65 years or older in England in 2015 was 11.4% (n = 61,177).
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• Overall, oral anticoagulation (OAC) was prescribed in 53.1% (n = 30,916) of patients with AF and a CHA2DS2-VASc
score of ≥2. OAC was more commonly prescribed in patients with frailty (adjusted odds ratio compared with fit, mild:
1.84 [95% confidence intervals 1.72–1.96]; moderate 2.34 [1.18–2.50] and severe 2.51 [2.33–2.71]).
• AF was associated with a 59% increased risk of mortality compared with patients without AF, regardless of the extent of
their frailty.
• After accounting for prescription of OAC and patient and clinical demographics, frailty was associated with an increased
risk of mortality, gastrointestinal bleeding and falls in patients with AF.
Introduction
At least 10 million people in Europe have a diagnosis of
atrial fibrillation (AF), which is associated with increased
risk of stroke and mortality [1, 2]. In particular, AF is
common amongst older people, affecting 7.2% of people
aged over 65 years, and 15.1% of those aged between 85
and 89 years [3, 4]. Given its association with age, many
people with AF also live with frailty—a condition in which
there is a decline in biological reserves and deterioration in
physiological mechanisms that render people vulnerable to
a range of adverse outcomes [5,6]. Although appropriate
prescription of oral anticoagulation (OAC) reduces stroke
risk by ∼64% and is associated with a mortality advantage,
there may be prescribing inertia for OAC in those with frailty
due to fears of iatrogenic harm [7–9].
Frailty is often more useful than chronological age
in guiding individualised treatment of older people with
cardiovascular disease in the context of advancing multi-
morbidity and polypharmacy [10,11]. However, despite an
increasing prevalence of both AF and frailty, comprehensive
community-based data are lacking to quantify the disease
burden, OAC prescription rates and clinical outcomes
for older people with AF and frailty [12]. This work
is particularly important given recent findings that the
association between frailty and increased cardiovascular
events and mortality appears to be independent of traditional
cardiovascular risk factors [13]. Frailty may be identified
using electronic health records (EHR) in primary care
using an electronic frailty index (eFI) [14], based upon
the cumulative deficit model [15]. The eFI has robust
predictive validity for outcomes of mortality, hospitalisation
and nursing home admission, and has convergent validity
against established frailty instruments [16]. In this study, we
describe the prevalence of both frailty and AF in patients
aged 65 years or older; evaluate OAC prescription rates; and
analyse clinical outcomes in patients with AF, according to
the degree of frailty.
Methods
Data and participants
This population-based cohort study used data from the
ResearchOne primary care database, which includes de-
identified clinical and administrative data derived from the
EHRs of patients registered at a general practice in England
using the SystmOne clinical system [17]. As of 2016, there
were 20.2 million patients registered in SystmOne, repre-
senting 35% of patients in England [18]. The analytical
cohort included 50.5 million ResearchOne records dating
back as far as 1 January 1986 for 536,955 patients aged
65 years or older by 31 December 2015. For each individual,
GP records were followed up until death, moving from a
ResearchOne practice, or the censoring date, 11th April
2017.
The AF group constituted those with a diagnosis of cur-
rent or resolved AF (paroxysmal, persistent and permanent)
or atrial flutter recorded in their primary care record on
or at any time before 31st December 2015. Patients with
a record of AF, but no date of diagnosis were excluded
(Supplementary Figure 1). AF was defined according to
a comprehensive list of clinical terms version-3 (CTV-3)
codes (data supplement). Frailty was estimated using the
eFI, in which the proportion of deficits (symptoms and
signs, abnormal laboratory values, disability or disease state)
from 36 possible deficits was calculated, categorised into fit
(0–0.12), mild (>0.12–0.24), moderate (>0.24–0.36) or
severe (>0.36) frailty [14]. With the exception of polyphar-
macy (≥5 prescriptions in preceding 12 months), deficits
were identified from every EHR preceding 31st December
2015 using CTV-3 codes defined in the eFI [14].
The primary outcomes were all-cause mortality and first
stroke (ischaemic or unspecified). Secondary outcomes were
first gastrointestinal or intracranial bleed, fall and TIA
(CTV-3 codes in the data supplement). Date of death from
any cause (aggregated at source to month and year) was
ascertained from the GP record and provided as part of the
anonymised patient-level dataset. Stroke risk in patients with
AF was calculated using the CHA2DS2-VASc score [19].
Scores range from zero to nine (higher scores indicating
greater stroke risk). Participants with scores of two or
more were considered eligible for OAC, in accordance with
guidelines [20,21].
Statistical analyses
Baseline characteristics including patient demographics (age,
sex, postcode level indices of multiple deprivation (IMD)
rank and residence in a nursing home) and medical history
(cancer, chronic kidney disease, diabetes, heart failure, hyper-
tension, hyperthyroidism, ischaemic heart disease, myocar-
dial infarction, pulmonary embolism, stroke [ischaemic or
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smoking [never vs. ever]) were described for patients with
and without AF. Numbers and percentages were presented
for categorical variables; means with standard deviations
(SD) or medians and interquartile range (IQR) for nor-
mally and non-normally distributed continuous variables
respectively.
A point-prevalence of AF with 95% confidence intervals
(CI) on 31 December 2015, and the proportion of those
with AF who were prescribed OAC (direct oral anticoagulant
[DOAC] or warfarin) of those eligible to receive treatment
were calculated. To determine the association between frailty
and OAC prescription, logistic regression models with
binary treatment outcome and categories of frailty were fitted
with adjustment for factors that may affect the risk of bleed-
ing or interact with anticoagulants: age; medical history of
cancer, varices, bleeding (gastrointestinal or intracranial), co-
prescription of an antiplatelet medication, and prescription
of steroid, non-steroidal anti-inflammatory drug, macrolide
antibiotic or proton-pump-inhibitor in the previous year
[22]. To account for practice level variation, models included
adjustment for GP practice identifiers (ID). An unadjusted
scatter plot showing the proportion of patients prescribed
OAC for a given eFI was generated (Supplementary
Figure 2).
Incidence rates of the first occurrence of each clinical
outcome were reported for individuals with and without
AF by frailty category and expressed per 1,000 person-
years (/1,000 pys). A series of Cox proportional hazards
models were fitted to determine the risk of mortality for
patients with and without AF (adjusted for age, sex, smoking,
IMD and GP practice), and for each outcome, stratified
by frailty category, amongst people with AF, and limited
to those with AF and eligible for OAC. Proportionality of
hazards was confirmed using a log–log survival plot, and
the risk of each outcome was estimated in the whole cohort
after adjusting for age, sex, smoking status and IMD at
time of study entry and practice ID. In patients with AF
and CHA2DS2Vasc ≥2 estimates were further adjusted for
prescription of antiplatelet and OAC. In this subgroup, Fine
and Gray competing risk models were implemented treating
death as a competing risk for non-fatal outcomes (presented
in Figure 1) [23], and because of increasing evidence for
sex inequalities in frailty-related outcomes, we stratified the
primary analyses by sex [24]. Missing data for baseline demo-
graphics were minimal (IMD missing in 6%), and all other
data were collected on a positive recording basis (whereby the
absence of a recorded diagnosis is treated as the absence of
that event). Therefore, no formal missing data strategy was
employed. Analyses were undertaken using Stata MP 14.0
(StataCorp LP, USA) with statistical significance determined
at P < 0.05.
The study proposal was approved by the ResearchOne
Project Committee (REC 11/NE/0184). As we made sec-
ondary use of pseudonymised patient level data collected in
the course of normal care, no further NHS research ethics
committee approval was required.
Results
The analytic cohort comprised 536,955 patients (54.2%
women, median age 73.8 years) from 384 practices in
England (Table 1). Data were missing for IMD in 32,336
(6.0%), with no missing sex or age data. The prevalence of
AF at study entry was 11.39% (95% CI 11.31–11.48%,
n = 61,177), and was higher with increased frailty (supple-
mentary Table 1). Of those with AF, 89.5% (n = 54,734)
had mild, moderate or severe frailty, compared with 55.4%
(n = 263,356) of individuals without AF. There were 671,135
person-years of follow-up.
Oral anticoagulation
Of patients with AF, 95.1% (n = 58,204) had a CHA2DS2-
Vasc score of ≥2 and were considered eligible for OAC
prescription, which was prescribed in 30,916 (53.1%)
(Supplementary Table 2). Of those prescribed OAC, 23.7%
(n = 7,329) were prescribed a DOAC. The mean CHA2DS2-
Vasc score in AF patients eligible for OAC was higher
with increased frailty category (fit 2.2 [SD 0.98]; mild
3.2 [1.2]; moderate 4.0 [1.3] and severe 5.0 [1.4]). Frailty
category was positively associated with prescription of OAC
(adjusted odds ratio compared with fit, mild: 1.84 [95%
CI 1.72–1.96]; moderate 2.34 [1.18–2.50] and severe 2.51
[2.33–2.71], Supplementary Figure 2).
Clinical outcomes
All-cause mortality
All-cause mortality rates were higher in patients with AF
compared with patients without AF (Table 2, adjusted HR
1.59 [95% CI 1.55–1.64]). Frailty was associated with
increased mortality for patients with AF and a CHA2DS2-
Vasc score of ≥2 (Figure 1). The magnitude of association
was larger in women (adjusted HR compared with fit,
mild: 1.80 [95% CI 1.33–2.42]; moderate: 2.64 [1.97–
3.55]; severe: 4.36 [3.25–5.85]) than in men (mild: 1.36
[1.08–1.70]; moderate: 2.36 [1.89–2.95]; severe: 3.97
[3.17–4.96]).
Stroke
The risk of stroke was 67% higher in participants with
AF compared with those without (adjusted HR 1.67, 95%
CI 1.48–1.88). After adjustment, and accounting for com-
peting risk of mortality, frailty was not associated with
increased stroke risk for patients with AF and eligible for
OAC (Figure 1). When the competing risks analysis was
stratified by sex, women with moderate or severe frailty
had an increased risk of stroke (adjusted HR comparing
with fit, mild: 2.31 [0.70–7.57], moderate: 3.94 [1.22–
12.75] and severe 3.63 [1.10–12.02]), but this was not the
case in men (adjusted HR comparing with fit, mild: 0.69
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Figure 1. Adjusted association between frailty category and clinical outcomes in patients with atrial fibrillation and eligible for oral
anticoagulation.
Adjusted for age, sex, smoking, indices of multiple deprivation, general practice identifier, oral anticoagulation and antiplatelet
prescription. Mortality was modelled as a competing risk for non-death outcomes.
Abbreviations GI: gastrointestinal; IC: intracranial; TIA: transient ischaemic attack.
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Table 1. Characteristics of patients by atrial fibrillation status at study entry
All n = 536,955 No AF n = 475,778 AF n = 61,177
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age. Median (IQR) 73.8 (69.0–80.5) 73.1 (68.8–79.6) 79.7 (73.3–85.5)
Women n (%) 290,764 (54.2) 262,777 (55.2) 27,987 (45.8)
IMD n (%)
Most deprived quintile 65,337 (13.0) 57,898 (13.0) 7,439 (12.9)
Least deprived quintile 122,726 (24.3) 109,281 (24.5) 13,445 (23.3)
Number of eFI deficits, median (IQR) 5 (3–8) 5 (3–8) 9 (6–12)
Frailty category n (%)
Fit 218,865 (40.8) 212,422 (44.7) 6,443 (10.5)
Mild 181,986 (33.9) 161,634 (34.0) 20,352 (33.3)
Moderate 91,411 (17.0) 71,096 (14.9) 20,315 (33.2)
Severe 44,693 (8.3) 30,626 (6.4) 14,067 (23.0)
Past medical history
Cancer 71,418 (13.3) 61,193 (12.9) 10,225 (16.7)
Chronic kidney disease 102,529 (19.1) 82,204 (17.3) 20,325 (33.2)
Diabetes 92,146 (17.2) 77,915 (16.4) 14,231 (23.3)
Heart failure 25,553 (4.8) 13,103 (2.8) 12,450 (20.4)
Hypertension 283,517 (52.8) 242,177 (51.0) 41,340 (67.6)
Hyperthyroid 10,875 (2.0) 8,873 (1.9) 2,002 (3.3)
Ischaemic heart disease 84,237 (15.7) 64,651 (13.6) 19,586 (32.0)
Myocardial infarction 32,802 (6.1) 25,383 (5.3) 7,419 (12.1)
Pulmonary embolism 9,597 (1.8) 7,718 (1.6) 1,879 (3.1)
Stroke 25,412 (4.7) 18,173 (3.8) 7,239 (11.8)
Infarct 10,593 (2.0) 7,414 (1.6) 3,179 (5.2)
Unspecified 17,982 (3.4) 12,939 (2.7) 5,043 (8.2)
Falls 56,407 (12.2) 53,649 (11.3) 11,758 (19.2)
Valvular heart disease 23,003 (4.3) 14,263 (3.0) 8,740 (14.3)
History of smoking 378,646 (70.7) 333,270 (70.3) 45,376 (74.3)
Abbreviation: n, number.
Table 2. Rates of clinical outcomes by AF status
No AF, n = 475,778 AF, n = 61,177 P value
Events (n) Rate (95% CI) Events (n) Rate (95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Death 18,111 30.34 (29.90, 30.79) 6,143 82.75 (80.70, 84.84) <0.001
Stroke 1,293 2.17 (2.05, 2.29) 398 5.38 (4.87, 5.93) <0.001
Infarct 696 1.17 (1.08, 1.26) 213 2.87 (2.51, 3.29) <0.001
Unspecified 705 1.18 (1.10, 1.27) 211 2.85 (2.49, 3.26) <0.001
Gastrointestinal bleed 2,653 4.46 (4.29, 4.63) 583 7.90 (7.29, 8.57) <0.001
Intracranial bleed 493 0.83 (0.76, 0.90) 136 1.83 (1.55, 2.17) <0.001
Falls 4.803 8.07 (7.84, 8.30) 1,421 19.23 (18.26, 20.26) <0.001
Transient ischaemic attack 1,992 3.34 (3.20, 3.49) 372 5.03 (4.54, 5.57) <0.001
Rates per 1,000 person years, with 95% CI.
Gastrointestinal and intracranial bleeding
The rates of gastrointestinal and intracranial bleeding were
higher in patients with AF than in those AF (Table 2). In
patients with AF and eligible for OAC the moderate and
severe frailty categories were at increased risk of GI bleed
compared with the fit group, but there was no association
between frailty category and IC bleeding events (Figure 1).
Falls
The rate of falls was higher in patients with AF than in those
without (Table 2). In patients with AF and eligible for OAC,
frailty was significantly associated with an increased risk of
falls. Participants in the severe frailty category were over eight
times more likely to fall than the fit group (adjusted HR 8.04
[4.60–14.03], Figure 1).
TIA
The rate of TIA was higher in patients with AF than those
without (Table 2). In patients with AF and eligible for OAC,
the adjusted HR did not vary significantly by frailty category
(Figure 1).
Discussion
In this community-based study of 536,995 older people,
one in nine had a diagnosis of AF—of whom almost 90%
had concomitant frailty. Patients with AF had higher rates
of all-cause mortality, stroke, bleeding, TIA and falls than
those without AF. Although overall OAC was prescribed in







/ageing/advance-article/doi/10.1093/ageing/afaa265/6035279 by guest on 14 January 2021
C. Wilkinson et al.
more common in patients with frailty. After accounting for
demographic profiles and treatment provision, patients with
AF and a CHA2DS2-Vasc score of ≥2 had an elevated risk of
mortality, GI bleeding, and falls with increasing frailty levels.
Women, but not men, had an increased stroke risk associated
with increased levels of frailty.
Stroke is a devastating condition—but in patients with
AF it is largely preventable through appropriate use of OAC.
Yet, prescription rates of OAC are low in eligible patients,
as in other studies [25–29]. In general, stroke disease is sig-
nificantly more common in older people than is intracranial
bleeding, even in the presence of OAC [30, 31]. However,
in this study, people with frailty more commonly had falls.
Although guidance suggests that OAC should not be with-
held solely because a person is at risk of falls, clinicians
are fearful of the risk of harm from head injury in those
that fall [21, 32, 33]. Other bleeding complications may be
poorly tolerated in people with frailty—who have a lower
physiological reserve to mount a full recovery [5, 34]. These
must be set against a higher absolute risk of stroke, and
therefore more needs to be done to understand and overcome
reasons for non-prescription of OAC [35].
Interestingly, in this study we showed a positive asso-
ciation between frailty and prescription rates, although
prescribing rates plateaued and dropped with more severe
frailty. Previous small studies have shown conflicting
findings—with one reporting a positive [36] and one
a negative association between OAC prescription and
phenotype-defined frailty status [37]. The present study
has the advantages of a large, representative community-
based dataset and a validated measure to ascertain frailty
status [16].
Despite a growing number of patients with AF and frailty,
data are lacking regarding the relative safety and efficacy
of OAC in this population [12]. Observational evidence
suggests the benefits of OAC may be similar for patients with
and without frailty [37]. Although people with moderate–
severe frailty are not well represented in randomised clinical
trials of the efficacy and safety of DOACs, recent post-
hoc analyses have shown that rates of stroke or systemic
embolism, death, and major bleeding are increased with
increased levels of frailty [38,39]. However, the efficacy
and safety of apixaban compared with warfarin was not
modified by multi-morbidity status [38], and a reduction in
bleeding was shown with edoxaban compared with warfarin
overall, but not significantly so in those with more advanced
frailty (who made up a small proportion of the overall trial
population) [39].
We have shown that frailty is common among patients
with AF and is associated with a poor prognosis. Our
finding that the risk of stroke is higher for women with
increasing frailty, but not men, is of interest. Women
tend to develop stroke disease at older ages than men
[40], and tend to live longer with a greater degree of co-
morbidity and frailty [24,41]. That many of the age-related
deficits are risk factors for stroke may, in part, explain this
observation.
Strengths and limitations
Evidence is gathering as to the importance of frailty beyond
traditional cardiovascular risk factors as a prognostic deter-
minant for in patients with cardiovascular disease [13, 42],
although data are lacking in evaluating this among patients
with AF [12]. We present the largest study of its kind to
investigate this important issue. Our estimates are adjusted
for confounders informed by the existing literature. In the
interests of transparency, we disclose our clinical outcome
codes [43]. However, we recognise the limitations of our
work. First, this work was observational and beholds inherit
bias associated with such designs; whereas we report associa-
tions this does not imply causation. Moreover, a randomised
controlled trial would be more appropriate methodology for
the investigation of efficacy and safety of OAC in AF with
frailty. Second, we had no role in the collection or processing
of the raw data from constituent General Practices; coding
practices may have changed over time [44]; and data were
not available for calculation of bleeding scores such as HAS-
BLED. Third, although recurrence of AF is more usual [45–
47], some individuals with a history of AF may have had
no recurrence during the study period, which may have
decreased the apparent association between AF and throm-
boembolism. Fourth, the dataset was not linked to secondary
care data, and secondary care diagnoses and investigations are
potentially under-reported [48]. Fifth, OAC status was ascer-
tained at study entry only; and although there is evidence
that the prescribed dosage of DOAC is frequently incorrect
[49], we did not have access to clinical data to verify dosage
or evaluate contraindications. Finally, we used the full eFI in
order to preserve generalisability. However, this meant that a
slightly higher frailty index is inevitable in patients with AF
(AF is 1 of 36 deficits).
Conclusion
Frailty is common among older people with AF. After
accounting for differences in demographics and treatment,
frailty was associated with an increased risk of mortality,
falls and gastrointestinal bleeding in this population. Just
half the patients with an elevated stroke risk and AF were
prescribed OAC, and patients with frailty were more likely
to be prescribed OAC than those without frailty. Although
it is possible that this represents holistic decision-making
with regard to primary prevention of stroke in a population
that are approaching the end of their lives, it is likely that
wider use of OAC in patients at risk of stroke will reduce the
burden of stroke and associated disability.
Supplementary Data: Supplementary data mentioned in
the text are available to subscribers in Age and Ageing online.
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